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Backgrounds: Approximately 1,000 microRNAs (miRs) are present in the human genome; however, little is known
about the regulation of miR transcription. Because miR levels are deregulated in chronic lymphocytic leukemia (CLL)
and signal transducer and activator of transcription (STAT)-3 is constitutively activated in CLL, we sought to
determine whether STAT3 affects the transcription of miR genes in CLL cells.
Methods: We used publically available data from the ENCODE project to identify putative STAT3 binding sites in
the promoters of miR genes. Then we transfected CLL cells with STAT3-shRNA or with an empty vector, and to
determine which miRs are differentially expressed, we used a miR microarray approach followed by validation of
the microarray results for 6 miRs using quantitative real-time polymerase chain reaction (qRT-PCR).
Results: We identified putative STAT3 binding sites in 160 promoter regions of 200 miRs, including miR-21, miR-29,
and miR-155, whose levels have been reported to be upregulated in CLL. Levels of 72 miRs were downregulated
(n = 63) or upregulated (n = 9). qRT-PCR confirmed the array data in 5 of 6 miRs.
Conclusions: The presence of activated STAT3 has a profound effect on miR expression in CLL cells.
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B-cell chronic lymphocytic leukemia (CLL) is characterized
by asymmetrical proliferation and apoptosis of leukemia
cells co-expressing the CD5 and CD19 antigens [1,2], and
several chromosomal abnormalities, including del(13q),
del(11q), del(17p), and trisomy 12, are detected in most,
but not all, cases. However, in almost all patients, regard-
less of their cytogenetic abnormalities, clinical characteris-
tics, disease stage, or treatment status, signal transducer
and activator of transcription 3 (STAT3) is constitutively
phosphorylated on serine 727 residue [3,4]. Phosphoserine
STAT3 shuttles to the nucleus, binds to DNA, and activates
genes known to be activated by phosphotyrosine STAT3
in other cell types [4]. Furthermore, unphosphorylated* Correspondence: zestrov@mdanderson.org
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reproduction in any medium, provided the orSTAT3, detected at high levels in CLL cells, constitutively
activates the transcription factor nuclear factor κB [5],
which is known to induce the production of several pro-
inflammatory cytokines and activate survival pathways.
STAT3-induced transcription of protein-coding genes
has been extensively studied in normal and neoplastic
tissues[6]. However, protein-coding genes comprise only
3% of the human genome [7] and only scant data are
available on the role of STAT3 in the transcription of
non-protein-coding genes. Although approximately 1000
microRNAs (miRs) collectively regulate more than 30%
of protein-coding genes [8], little is known about miR
gene transcription. Iliopoulos et al. found that STAT3
activates the transcription of miR-21 and miR-181b-1,
thereby inducing a stable transformed state in cancer
cell lines [9].
Because STAT3 is constitutively activated in CLL cells
and recent data demonstrated a global deregulation ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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STAT3 affects the expression of miRs in CLL cells.
Therefore, we analyzed publicly available data to deter-
mine whether STAT3 binds to miR promoters, and studies
the effect of STAT3 on miR expression in CLL cells.Methods
Data mining
To find the putative promoter sites of miR genes, we
used data on H2K4me3 enrichment regions published
by Baer et al. [11]. To find STAT3 binding sites on these
promoters, we used chromatin immunoprecipitation
followed by high-throughput DNA sequencing (ChIP-seq)
data (Additional file 1: Figure S1), generated as part of the
ENCODE project [12] and acquired from the University
of California Santa Cruz genome browser. For each puta-
tive STAT3 binding event a cluster score representing the
ChIP-seq signal strength, ranging from 0 to 1000, was
assigned.Patient samples and cell fractionation
After obtaining The University of Texas MD Anderson
Cancer Center Institutional Review Board-approved in-
formed consent, we obtained peripheral blood (PB) cells
from 3 patients with CLL. To isolate low-density cells,
we fractionated PB cells using Ficoll Hypaque 1077
(Sigma-Aldrich). More than 90% of the CLL PB cells
were CD19+/CD5+ lymphocytes.Generation of green fluorescence protein (GFP)-lentiviral
STAT3-shRNA and infection of CLL cells
293T cells were co-transfected with GFP-lentivirus
STAT3 short hairpin RNA (shRNA) or GFP-lentivirus
empty vector and the packaging vectors pCMVdeltaR8.2
and pMDG (generously provided by Dr. G. Inghirami,
Torino, Italy) using the Superfect transfection reagent
(Qiagen, Inc.). 293T cell culture medium was changed
after 16 hours and collected after 48 hours. The culture
medium was filtered through a 45-μm syringe filter to
remove floating cells, the lentivirus was then concen-
trated by filtration through an Amicon ultracentrifugal
filter device (Millipore, Billerica, MA), and the concen-
trated supernatant was used to infect CLL cells. CLL
cells (5 × 106/mL) were incubated in 6-well plates
(Becton Dickinson, Franklin Lakes, NJ) in 2 ml DMEM
supplemented with 10% fetal calf serum and transfected
with 100 μL of viral supernatant. Polybrene (10 ng/mL)
was added to the viral supernatant at a ratio of 1:1000
(v/v). Infection efficiency was measured after 48–72
hours and was found to range between 40% and 70%
(calculated on the basis of the ratio of propidium iodide
(PI)-negative/GFP-positive cells).RNA purification and quantitative real-time polymerase
chain reaction (RT-PCR)
Total RNA was extracted using Trizol reagent (Invitrogen)
for microRNA analyses according to the manufacturer's
protocol. For mature microRNA expression analysis,
total RNA was retrotranscribed with microRNA-specific
primers using TaqMan microRNA reverse transcription
kit (Applied Biosystems, Foster City, CA), and then
quantitative RT-PCR was performed using Taqman miR
assays according to the manufacturer's protocol. The
comparative cycle time (Ct) method was used to calculate
the relative abundance of microRNAs compared with
snRNA U6 as an internal control for RNA normalization.
The profiling was done in duplicate wells for each sample
and in two independent experiments (three measurements
each), and the results were presented as mean +/− SD of
the four measurements.
Western immunoblotting
Western blot analysis was conducted using mouse anti-
human STAT3 antibodies (BD Bioscience, Palo Alto, CA)
and horseradish peroxidase-conjugated anti-mouse second-
ary antibodies (GE, healthcare, Amersham, Buckinghamshire,
UK), as previously described [4].
Microarray analysis
Microarray analysis was conducted to identify miRs that
were differentially expressed after silencing of STAT3 by
transfection with short hairpin (sh) RNA or control treat-
ment by transfection with empty vector. RNA was labeled
and hybridized on miR microarray chips as previously
described [13]. Signals in the images were quantified with
GenePix Pro 6.0 software (Axon Instruments), and data
were analyzed using PartekFlow software (v 2.1, 2012).
Following quantile normalization, expression differences
between the two sets of transfected CLL cells were tested
by application of the Welch’s approximate t-test for two
groups (with variances not assumed equal), with a P value
cutoff of 0.05. Hierarchical clustering was generated for
both genes and conditions, by using standard correlation
as a measure of similarity.
Bioinformatics tools
The RNA22 pattern discovery algorithm, which utilizes
miR sequences to predict miR:mRNA heteroduplexes,
was used to simulate the sponge-out process [14].
Results and discussion
Putative STAT3 binding sites exist in the promoters of
25% of miR genes
A histone modification in which histone H3 is trime-
thylated on lysine 4 residues (H2K4me3) typifies tran-
scription start sites in most gene promoters [15]. To
identify miR gene promoters, Baer et al. interrogated
Rozovski et al. Molecular Cancer 2013, 12:50 Page 3 of 6
http://www.molecular-cancer.com/content/12/1/50these regions in CLL cells, normal B cells, and CLL-
related cell lines [11]. Among the 939 miRs annotated
to the miRBase15 database [16], they identified putative
miR promoters in 781 miR genes [11].
Using those reports’ and the ChIP-seq ENCODE’s data
[12], we searched for STAT3-binding sites in miR pro-
moters. In our search, we identified 52,348 plausible
STAT3-binding sites; STAT3 binding sites were found in
160 putative promoters of nearly 25% of the miR genes
examined (N=200) with binding scores ranging from 100
(the lowest score) to 1000 (the highest score). Binding
sites were found in 132 promoters of single pre-miR
genes and in 28 promoters of pre-miR clusters of 2 to 6
genes (Table 1 and Additional file 2: Table S1). High
STAT3-binding scores of 1000 and 710 were identifiedTable 1 MiRs with putative STAT3 binding sites
Micro RNA gene Chromosome Promoter start coordinates
miR-1205, miR-1206,miR-1207 8 q24.21 128961454
miR-1537 1 q42.3 236045425
miR-21 17 q23.1 57901872
miR-3124 1 q44 249115404
miR-451 17q11.2 27222251
miR-92b 1 q22 155162340
miR-3197 21 q22.2 42537544
miR-646 20 q13.33 58712550
miR-629 15 q23 70383751
miR-30e, miR-30c-1 1 p34.2 41173077
miR-3125 2 p24.3 12855381
miR-3145 6 q23.3 138776942
miR-645 20 q13.13 49199911
miR-1256 1 p36.12 21346830
miR-619 12 q24.11 109248263
miR-181a-2, miR-181b-2 9 q33.3 127418928
miR-29a, miR-29b-1 7 q32.3 130583383
miR-202 10 q26.3 135069499
miR-3142, miR-146a 5 q34 159890882
miR-548c 12 q14.2 65000968
miR-630 15 q24.1 72764289
miR-135b 1 q32.1 205416952
miR-29c, miR-29b-2 1 q32.2 207991044
miR-1825 20 q11.21 30791020
miR-548h-1 14 q23.2 64578834
miR-612 11 q13.1 65183633
miR-148b 12 q13.13 54717640
miR-3174 15 q26.1 90543381
let7a-3, let7b 22 46480680
miR-1255a 4 q24 102263848
*MiRs with the highest STAT3 binding score obtained by using the ENCODE ChIP-sein miR-21 and miR-181b, consistent with the data of
Iliopoulos et al. [9]. Remarkably, putative STAT3-
binding sites were also detected in the promoters of
miR-15-1 and miR-16a, which are deleted in most CLL
patients with del(13q) [17].
STAT3 upregulates miR levels in CLL cells
Because putative STAT3 binding sites were identified in
a significant number of miR promoters and STAT3 is
constitutively activated in CLL, we sought to determine
whether STAT3 would affect miR levels in unstimulated
PB CLL cells. Transfection of CLL with STAT3-
shRNA downregulated STAT3-mRNA and protein
levels (Figure 1A). Microarray analysis showed that




















































































































































Figure 1 (See legend on next page.)
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Figure 1 Transfection with STAT3-shRNA alters miR gene expression in CLL cells. A. Left panel: Quantitative RT-PCR shows an 8 fold
reduction in STAT3 mRNA levels in CLL cells transfected with STAT3-shRNA compared to control CLL cells transfected with an empty vector. The
means ± S.D. of 3 experiments are depicted. Right panel: Western immunobloting shows a decrease in STAT3 protein levels of CLL cells
transfected with STAT3-shRNA compared to untreated cells or cells transfected with an empty vector. B. MiR array heat map depicts 23 miRs
whose expression differed significantly between CLL cells transfected with STAT3-shRNA and CLL cells transfected with empty vector. Red, high
levels; blue, low levels. C. Panels a through f show the results of RT-PCR analysis of CLL cells transfected with STAT3-shRNA. The plots show
relative expression as means ± SD of 3 replicates for each miR tested. Shown are relative expression of miRs in the unsorted STAT3-shRNA
transfected CLL cells (transfection efficiency: 30%; middle, gray bars), sorted STAT3-shRNA-transfected CLL cells (black bars), and empty vector-
transfected cells (light gray bars labeled “control”).
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vector-transfected cells in 152 probes from 78 non-coding
RNA genes, including 72 miR genes; the levels of 63 of the
72 miR genes were significantly downregulated by STAT3-
shRNA, suggesting that STAT3 upregulates the levels of
those miRs (Additional file 3: Table S2). For 60% of the 63
downregulated miR genes (n = 38) ChIP-seq data con-
firmed STAT3 binding in a putative promoter upstream of
the gene location, significantly more than expected by
chance (p<0.0001) (Additional file 2: Table S1).
To confirm these data, we studied miR levels of CLL
cells transfected with STAT3-shRNA or empty vector
using RT-PCR. Analyzed were miRs with either high levels
of STAT3-binding sites, as reported in the ChIP-seq data-
base (i.e. miR-21), reduced STAT3 levels following trans-
fection with STAT3-shRNA in our studies (miR-181a),
high STAT3-binding scores (213 for miR15-1 and miR-
16a and 1,000 for miR-21), or a known pathogenetic role
in CLL (miR15-1, miR-16a, miR-155, and miR-21) [18-20].
As shown in Figure 1B, RT-PCR confirmed the array data
in 5 of the 6 studied miRs.
STAT3 downregulates miR levels in CLL cells
Phosphorylated STAT3 binds to and activates the STAT3
gene, inducing the production of STAT3 protein [4]. Our
current analysis revealed that STAT3 binds several miRs
whose levels are overexpressed in CLL such as miR-21, an
oncomiR of various neoplasms [20], and miR-29 and
-181a, which affect CLL cell survival [21]. The levels of
most miRs we studied were downregulated by transfection
with STAT3-shRNA; however, the levels of 9 miRs were
upregulated (Figure 1; Additional file 3: Table S2),
suggesting that STAT3 downregulates those miRs’ levels.
Several pathways can lead to STAT3 mediated suppression
of transcription. Direct binding of unphosphorylated
STAT3 suppresses transcription [22]. For example, miR-
451, whose levels are downregulated by STAT3, carries a
very high STAT3 binding score in its promoter. In
addition, STAT3 mediates epigenetic silencing of a variety
of genes [23], in particular genes that affect histone
deacetylases [24,25]. Therefore, we theorized that STAT3
induces epigenetic silencing of various miRs in CLL cells.
Finally, STAT3 may also operate in a transcription-
independent fashion. Single-stranded RNAs were shownto sequester (“sponge”) miRs in a sequence-specific
manner [26]. Because constitutively phosphorylated
STAT3 activates the STAT3 gene, single-stranded 4.3-
kb STAT3-mRNA is generated at high levels in CLL
cells. Those 4.3-kb RNA strands may bind complemen-
tary miRs, thereby interrupting their interaction with
their corresponding target genes. For example, miR-18-a
antisense (AS), upregulated by STAT3-shRNA has a
complementary sequence in STAT3 mRNA, consistent
with the “sponge regulation” hypothesis. Conversely, the
miR-18-a sense form, downregulated by STAT3-shRNA,
does not have a complementary sequence in STAT3 or
the 3’UTR-STAT3.
To test whether this mechanism may be operative in
CLL cells, we performed a simulation analysis using the 9
miRs whose levels were upregulated by STAT3-shRNA.
We compared the theoretical energy released by single-
stranded STAT3 mRNA sequences to that of random
4.3-kb mRNA sequences with an identical base content.
Because miRs preferentially bind 3’-untranslated region
sequences, we also calculated the energy release of
shorter mRNA sequences. Using the RNA22 algorithm,
we found higher energy release by full-length and short
3’-untranslated region STAT3 mRNA than by random
single-stranded RNA sequences, suggesting that comple-
mentary binding of single-stranded STAT3 mRNA to
miRs sequestered the circulating miRs, generating a stable,
energetically superior state (Additional file 3: Table S2).
Taken together, our data suggest that STAT3 directly
and indirectly modulates miR expression in CLL cells.
Further studies to explore the mechanisms that affect
miR expression in CLL are warranted.
Additional files
Additional file 1: Genomic coordinates of STAT3 in miRs genes
promoters.
Additional file 2: Table S1. List of 160 miRs whose promoters harbor
putative STAT3 binding sites.
Additional file 3: Table S2. Simulation of energy released from STAT3
true single-stranded RNA and random RNA sequences in 9 miRs
upregulated by STAT3-shRNA.
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